AbClonal Science, Inc.

25 patents currently held · Updated Nov 14, 2026

Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.

Ending by 2030

Mar 2040

Next term end

When these terms end

5 yrs10 yrs20 yrs

Held patents by the year their term ends

20262027202820292030203120322033203420352036203720382039204020412042204320442045

Fee deadlines

Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.

1 fee due Dec 27, 2026
The maintenance fee for T4 DNA ligase variants with increased resistance to salt (US 11,685,913) comes due Dec 27, 2026. Unpaid by Jun 28, 2027, it lapses early.
2 fees due Mar 5 to 26, 2027 · next Mar 5
2 fees due Apr 10 to 17, 2027 · next Apr 10
1 fee due May 21, 2027
The maintenance fee for Mutant Taq Polymerase for Faster Amplification (US 11,821,010) comes due May 21, 2027. Unpaid by Nov 22, 2027, it lapses early.

Which patents, and when each one lapses · Pro

Recent changes

Nothing was recorded against this company's patents in the last 90 days.

Patents held now

Soonest term end first. Each date below is computed on that patent's own page, which shows the rule, the adjustments and the fee history it was derived from.

Patent	Title	Status	Expires	Confidence
US 10,865,441	Mutant Taq Polymerase for Faster Amplification In force Term ends Mar 9, 2040 · High confidence	In force	Term ends Mar 9, 2040	High confidence
US 11,168,312	Mutant taq polymerase for amplification in increased salt concentration or body fluids In force Ends no later than Mar 9, 2040 · From the USPTO record	In force	Ends no later than Mar 9, 2040	From the USPTO record
US 11,613,738	Mutant Taq Polymerase Resistant to Inhibition of Amplification in the Presence of Cyanine Dye In force Term ends Mar 9, 2040 · High confidence	In force	Term ends Mar 9, 2040	High confidence
US 11,649,441	Taq DNA Polymerase Mutants for Probe qPCR In force Term ends Mar 9, 2040 · High confidence	In force	Term ends Mar 9, 2040	High confidence
US 11,821,010	Mutant Taq Polymerase for Faster Amplification In force Term ends Mar 9, 2040 · High confidence	In force	Term ends Mar 9, 2040	High confidence
US 12,258,590	Mutant Taq Polymerase Providing Faster Amplification In force Term ends Mar 9, 2040 · High confidence	In force	Term ends Mar 9, 2040	High confidence
US 12,467,040	Mutant Taq polymerase for increased salt concentration or body fluids In force Term ends Mar 9, 2040 · From the USPTO record	In force	Term ends Mar 9, 2040	From the USPTO record
US 10,920,202	Thermolabile Serratia Marcescens nuclease In force Term ends Aug 20, 2040 · From the USPTO record	In force	Term ends Aug 20, 2040	From the USPTO record
US 11,020,474	Producing Recombinant SARS-CoV-2 Spike Protein in a Pre-fusion State In force Term ends Aug 25, 2040 · High confidence	In force	Term ends Aug 25, 2040	High confidence
US 10,947,518	Using Proteases to Control Restriction Enzyme Activity In force Term ends Oct 2, 2040 · High confidence	In force	Term ends Oct 2, 2040	High confidence

10 of 25 patents shown.

Pro members see all 25.

Pro members: see all 25 patents

Sources and methods

Compiled from the USPTO record, grants, published applications and recorded assignments, not yet reviewed by hand. How this record was built

Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.

Export every term end as CSV · Pro

Published applications

US patent applications published under this name that have not become patents. An application is published about eighteen months after its earliest filing; one that has not been published is in no public record.

4 pending · 3 no status recorded

List them